← back to search

Bradley M. Broom

The University of Texas MD Anderson Cancer Center · US
Area of research
Oncology · Immunology
Research interest
Research interests include PARP inhibition in cancer therapy, interferon and immune responses, Prostate Cancer Treatment and Research, and Cancer Genomics and Diagnostics.
h-index
60
citations
59,351
works
523
NIH funding
primary concept
email

Recent publications

Single-cell chromatin accessibility reveals malignant regulatory programs in primary human cancers
Science 2024cited by 41position: middledoi
FuncPEP v2.0: An Updated Database of Functional Short Peptides Translated from Non-Coding RNAs
Non-Coding RNA 2024cited by 4position: middledoi
SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
Clinical Cancer Research 2023cited by 23position: middledoi
Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting
Clinical Cancer Research 2020cited by 33position: middledoi
The Structure-Function Relationship of Angular Estrogens and Estrogen Receptor Alpha to Initiate Estrogen-Induced Apoptosis in Breast Cancer Cells
Molecular Pharmacology 2020cited by 23position: middledoi
Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ERα-positive breast cancer
Exploration of Targeted Anti-tumor Therapy 2020cited by 7position: middledoi
The Immune Landscape of Cancer
Immunity 2019cited by 799position: middledoi
PARP Inhibition Suppresses GR–MYCN–CDK5–RB1–E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer
Clinical Cancer Research 2019cited by 77position: middledoi
The Immune Landscape of Cancer
Immunity 2018cited by 6,153position: middledoi
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
Cell 2018cited by 3,906position: middledoi
Oncogenic Signaling Pathways in The Cancer Genome Atlas
Cell 2018cited by 3,331position: middledoi
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer
Cell 2018cited by 2,670position: middledoi
Comprehensive Characterization of Cancer Driver Genes and Mutations
Cell 2018cited by 2,493position: middledoi
Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation
Cell 2018cited by 2,331position: middledoi
The chromatin accessibility landscape of primary human cancers
Science 2018cited by 1,316position: middledoi
Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas
Cell Reports 2018cited by 1,220position: middledoi
Genomic and Functional Approaches to Understanding Cancer Aneuploidy
Cancer Cell 2018cited by 1,182position: middledoi
Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images
Cell Reports 2018cited by 1,045position: middledoi
Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients
Cancer Cell 2018cited by 954position: middledoi
Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines
Cell Systems 2018cited by 936position: middledoi
Pathogenic Germline Variants in 10,389 Adult Cancers
Cell 2018cited by 879position: middledoi
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma
Cell Reports 2018cited by 800position: middledoi
Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas
Cancer Cell 2018cited by 709position: middledoi
A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers
Cancer Cell 2018cited by 697position: middledoi
Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer
Cell Reports 2018cited by 511position: middledoi
lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer
Cancer Cell 2018cited by 485position: middledoi
Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas
Cell Systems 2018cited by 441position: middledoi
Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics
Cell 2018cited by 434position: middledoi
Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers
Cell Reports 2018cited by 390position: middledoi
Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas
Cell Reports 2018cited by 365position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Timothy C. Thompson · The University of Texas MD Anderson Cancer Center4 papers (2016–2023)Paul G. Corn · The University of Texas MD Anderson Cancer Center4 papers (2016–2023)Patricia Troncoso · The University of Texas MD Anderson Cancer Center3 papers (2016–2019)Guang Yang · Jinan University3 papers (2016–2019)Ganiraju C. Manyam · The University of Texas MD Anderson Cancer Center3 papers (2019–2024)Likun Li · Nanjing Agricultural University3 papers (2016–2019)Michael J. Overman · The University of Texas MD Anderson Cancer Center3 papers (2013–2020)Scott Kopetz · The University of Texas MD Anderson Cancer Center3 papers (2013–2020)Christian Pilarsky · Center for Cancer Research2 papers (2013–2013)Spyridon P. Basourakos · University Hospitals of Cleveland2 papers (2016–2017)Philipp Y. Maximov · Moscow Institute of Physics and Technology2 papers (2020–2020)Jeri Kim · The University of Texas MD Anderson Cancer Center2 papers (2016–2017)Dimitrios Korentzelos · University of Pittsburgh Medical Center2 papers (2017–2019)Michael A. Davies · IT University of Copenhagen2 papers (2013–2013)Jiexin Zhang · The University of Texas MD Anderson Cancer Center2 papers (2013–2013)Stanley R. Hamilton · City Of Hope National Medical Center2 papers (2013–2013)Ping Fan · University of Science and Technology of China2 papers (2020–2020)Jianxiang Wang · Zhejiang University2 papers (2016–2017)James L. Abbruzzese · Duke Cancer Institute2 papers (2013–2013)Bo Liu · Chengdu Fifth People's Hospital2 papers (2017–2019)